Alnylam Pharmaceuticals, Inc. ALNY
161.08 USD +1.19 (+0.74%)
At closeNov 4, 2026, 6:35 PM EST
163.07 +1.99 +1.24%
After hours · Nov 4, 6:35 PM ET
160.29 Day range 170.49
156.00 52-week range 479.79
- YTD
- -59.49%
- 1 year
- -61.96%
Analyst view
Consensus: buy
Buy
Price target (mean) 302.48 +87.8% upside
Now 161.08
- Target (low)
- 180.00
- Target (mean)
- 302.48
- Target (high)
- 455.00
Ratings (0m) 30 21 buy · 9 hold · 0 sell
- Strong buy7
- Buy14
- Hold9
- Sell0
- Strong sell0
Recommendation trend
- This month 30
- 1 month ago 30
- 2 months ago 29
- 3 months ago 29
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.33 | 1.47 – 3.11 | 1.25 | +86.7% | 1.52B | +38.7% | 13 |
| Next quarter | 2.72 | 1.80 – 3.59 | 1.99 | +36.5% | 1.54B | +32.1% | 8 |
| Current year | 22.61 | 21.55 – 24.71 | 5.08 | +345.1% | 5.44B | +46.4% | 14 |
| Next year | 11.15 | 7.28 – 17.71 | 22.61 | -50.7% | 6.57B | +20.8% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Barclays | Maintained | Overweight | Overweight |
| Nov 2, 2026 | Truist Securities | Downgrade | Buy | Hold |
| Nov 2, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 30, 2026 | UBS | Maintained | Buy | Buy |
| Oct 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 30, 2026 | Bernstein | Downgrade | Outperform | Market Perform |
| Oct 30, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Oct 30, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 30, 2026 | Raymond James | Downgrade | Strong Buy | Outperform |
| Oct 29, 2026 | Needham | Maintained | Buy | Buy |
| Oct 14, 2026 | Citigroup | Maintained | Buy | Buy |
| Oct 14, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 21, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2026 | Jefferies | Maintained | Hold | Hold |
| Sep 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 19, 2026 | BMO Capital | Initiated | Outperform | Outperform |
| Aug 14, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 4, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 3, 2026 | Raymond James | Upgrade | Outperform | Strong Buy |
| Aug 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 3, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 31, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 31, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 31, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 31, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
